The current PE ratio of PCRX can't be determined, as the TTM EPS of -$1.97 is negative. The last PE ratio of Pacira BioSciences, recorded in June 2024, was 20.88.
The PE ratio of Pacira BioSciences has averaged 217.83 over the last ten years. Over the past ten years, PCRX's PE ratio was at its highest in the Dec 2015 quarter at 1,535.8, when the stock price was $76.79 and the EPS was $0.05. The lowest value was in the Jun 2021 quarter, when it reached 15.09 with a price of $60.68 and an EPS of $4.02.
Maximum annual increase: 260.91% in 2021
Maximum annual decrease: -66.39% in 2023
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
2023 | 37.08 | -66.39% | $33.74 | $0.91 |
2022 | 110.31 | 74.16% | $38.61 | $0.35 |
2021 | 63.34 | 260.91% | $60.17 | $0.95 |
2020 | 17.55 | N/A | $59.84 | $3.41 |
2019 | N/A | N/A | $45.3 | -$0.27 |
2018 | N/A | N/A | $43.02 | -$0.01 |
2017 | N/A | N/A | $45.65 | -$1.07 |
2016 | N/A | N/A | $32.3 | -$1.02 |
2015 | 1,535.8 | N/A | $76.79 | $0.05 |
2014 | N/A | N/A | $88.66 | -$0.39 |
2013 | N/A | N/A | $57.49 | -$1.93 |
2012 | N/A | N/A | $17.47 | -$1.72 |
2011 | N/A | N/A | $8.65 | -$2.64 |
2010 | N/A | N/A | N/A | -$47.29 |
2009 | N/A | N/A | N/A | -$55.32 |
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
Sep 2024 | N/A | N/A | $15.05 | -$1.97 |
Jun 2024 | 20.88 | 8.64% | $28.61 | $1.37 |
Mar 2024 | 19.22 | -48.17% | $29.22 | $1.52 |
Dec 2023 | 37.08 | -83.08% | $33.74 | $0.91 |
Sep 2023 | 219.14 | N/A | $30.68 | $0.14 |
Jun 2023 | N/A | N/A | $40.07 | -$0.11 |
Mar 2023 | N/A | N/A | $40.81 | -$0.23 |
Dec 2022 | 110.31 | -6.68% | $38.61 | $0.35 |
Sep 2022 | 118.2 | 76.39% | $53.19 | $0.45 |
Jun 2022 | 67.01 | -24.49% | $58.3 | $0.87 |
Mar 2022 | 88.74 | 40.1% | $76.32 | $0.86 |
Dec 2021 | 63.34 | 57.21% | $60.17 | $0.95 |
Sep 2021 | 40.29 | 167% | $56 | $1.39 |
Jun 2021 | 15.09 | -26.35% | $60.68 | $4.02 |
Mar 2021 | 20.49 | 16.75% | $70.09 | $3.42 |
Stock name | PE ratio | Market cap |
---|---|---|
DRRX Durect Corp | N/A | $24.8M |
HRTX Heron Therapeutics Inc | N/A | $263.12M |
CPIX Cumberland Pharmaceuticals Inc | N/A | $74.56M |
CARA Cara Therapeutics Inc | N/A | $22.72M |
OMER Omeros Corp | N/A | $531.98M |
PCRX Pacira BioSciences Inc | N/A | $1.16B |
The current price to earnings ratio of PCRX can't be calculated, as its EPS of -$1.97 is negative.
The 3-year average PE ratio for PCRX stock is 85.07.
The 5-year average PE ratio for PCRX stock is 61.28.
The highest quarterly PE ratio in the last ten years has been 1,535.8 and it was in the Dec 2015 quarter.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.